NextCure, Inc. (NXTC): Total Assets
$50.18M
As of 2025-12-31
$22.62M
As of 2026-06-30
-35.2%
3-year compound annual growth
-30.4%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $50.18M | -37.9% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $80.86M | -36.8% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $128.04M | -30.5% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $184.16M | -24.0% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $242.39M | -21.0% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $306.64M | -13.9% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $356.17M | +141.3% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $147.63M | n/a | 2020-03-12, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| NextCure, Inc. (NXTC) | 2025-12-31 | $50.18M | -37.9% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $50.24M | +36.3% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $49.95M | +12.6% |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $49.13M | +55.2% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $51.77M | -32.7% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $48.56M | -42.4% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $47.89M | -5.3% |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $47.61M | -37.7% |
| Spruce Biosciences, Inc. (SPRB) | 2025-12-31 | $53.02M | +17.3% |
Compare NXTC, IRD, COYA, UNCY side by side · Screen every company in Pharmaceutical Preparations ↗